266 related articles for article (PubMed ID: 14573759)
1. Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor.
Incles CM; Schultes CM; Kelland LR; Neidle S
Mol Pharmacol; 2003 Nov; 64(5):1101-8. PubMed ID: 14573759
[TBL] [Abstract][Full Text] [Related]
2. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function.
Burger AM; Dai F; Schultes CM; Reszka AP; Moore MJ; Double JA; Neidle S
Cancer Res; 2005 Feb; 65(4):1489-96. PubMed ID: 15735037
[TBL] [Abstract][Full Text] [Related]
3. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Raju U; Nakata E; Mason KA; Ang KK; Milas L
Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
[TBL] [Abstract][Full Text] [Related]
4. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
Jung C; Motwani M; Kortmansky J; Sirotnak FM; She Y; Gonen M; Haimovitz-Friedman A; Schwartz GK
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6052-61. PubMed ID: 14676132
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol.
Smith V; Raynaud F; Workman P; Kelland LR
Mol Pharmacol; 2001 Nov; 60(5):885-93. PubMed ID: 11641415
[TBL] [Abstract][Full Text] [Related]
6. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
[TBL] [Abstract][Full Text] [Related]
8. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of acridine-based telomerase inhibition and telomere shortening.
Gunaratnam M; Greciano O; Martins C; Reszka AP; Schultes CM; Morjani H; Riou JF; Neidle S
Biochem Pharmacol; 2007 Sep; 74(5):679-89. PubMed ID: 17631279
[TBL] [Abstract][Full Text] [Related]
11. Rhabdoid tumor growth is inhibited by flavopiridol.
Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
[TBL] [Abstract][Full Text] [Related]
12. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.
Jiang J; Matranga CB; Cai D; Latham VM; Zhang X; Lowell AM; Martelli F; Shapiro GI
Cancer Res; 2003 Nov; 63(21):7410-22. PubMed ID: 14612540
[TBL] [Abstract][Full Text] [Related]
13. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication.
Chao SH; Fujinaga K; Marion JE; Taube R; Sausville EA; Senderowicz AM; Peterlin BM; Price DH
J Biol Chem; 2000 Sep; 275(37):28345-8. PubMed ID: 10906320
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Motwani M; Li X; Schwartz GK
Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717
[TBL] [Abstract][Full Text] [Related]
15. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
Ambrosini G; Seelman SL; Qin LX; Schwartz GK
Cancer Res; 2008 Apr; 68(7):2312-20. PubMed ID: 18381438
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
Nguyen DM; Schrump WD; Tsai WS; Chen A; Stewart JH; Steiner F; Schrump DS
J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887
[TBL] [Abstract][Full Text] [Related]
17. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
18. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.
Li W; Fan J; Bertino JR
Cancer Res; 2001 Mar; 61(6):2579-82. PubMed ID: 11289134
[TBL] [Abstract][Full Text] [Related]
19. Flavopiridol binds to duplex DNA.
Bible KC; Bible RH; Kottke TJ; Svingen PA; Xu K; Pang YP; Hajdu E; Kaufmann SH
Cancer Res; 2000 May; 60(9):2419-28. PubMed ID: 10811119
[TBL] [Abstract][Full Text] [Related]
20. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
Bible KC; Boerner SA; Kirkland K; Anderl KL; Bartelt D; Svingen PA; Kottke TJ; Lee YK; Eckdahl S; Stalboerger PG; Jenkins RB; Kaufmann SH
Clin Cancer Res; 2000 Feb; 6(2):661-70. PubMed ID: 10690552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
